James E. Barrett

Drexel University, Philadelphia, PA, United States 
"James Barrett"
Mean distance: 16.42 (cluster 19)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Barrett JE, Haas DA. (2016) Perspectives and Trends in Pharmacological Approaches to the Modulation of Pain Advances in Pharmacology
Barrett JE. (2015) The pain of pain: challenges of animal behavior models. European Journal of Pharmacology. 753: 183-90
Zhang L, Li CT, Su TP, et al. (2011) P11 expression and PET in bipolar disorders. Journal of Psychiatric Research. 45: 1426-31
Dunlop J, Watts SW, Barrett JE, et al. (2011) Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. The Journal of Pharmacology and Experimental Therapeutics. 337: 673-80
Zhang L, Su TP, Choi K, et al. (2011) P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. Journal of Psychiatric Research. 45: 435-41
Barrett JE. (2010) mGluR2-Positive allosteric modulators: Therapeutic potential for treating cocaine abuse? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 2007-8
Su TP, Zhang L, Chung MY, et al. (2009) Levels of the potential biomarker p11 in peripheral blood cells distinguish patients with PTSD from those with other major psychiatric disorders. Journal of Psychiatric Research. 43: 1078-85
Barrett JE. (2008) Pioneer in behavioral pharmacology: a tribute to Joseph V. Brady. Journal of the Experimental Analysis of Behavior. 90: 405-15
Barrett JE, Bergman J. (2008) Peter B. Dews and pharmacological studies on behavior. The Journal of Pharmacology and Experimental Therapeutics. 326: 683-90
Rosenzweig-Lipson S, Sabb A, Stack G, et al. (2007) Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology. 192: 159-70
See more...